ProfileGDS5678 / 1436421_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 83% 84% 85% 80% 79% 83% 81% 82% 83% 86% 82% 82% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7621881
GSM967853U87-EV human glioblastoma xenograft - Control 26.1022483
GSM967854U87-EV human glioblastoma xenograft - Control 36.2603584
GSM967855U87-EV human glioblastoma xenograft - Control 46.6123185
GSM967856U87-EV human glioblastoma xenograft - Control 55.7618780
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3811379
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9151983
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7735281
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8989282
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0522483
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5416486
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0147782
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.976882
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.4598986